AU2012229443B2 - Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia - Google Patents

Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia Download PDF

Info

Publication number
AU2012229443B2
AU2012229443B2 AU2012229443A AU2012229443A AU2012229443B2 AU 2012229443 B2 AU2012229443 B2 AU 2012229443B2 AU 2012229443 A AU2012229443 A AU 2012229443A AU 2012229443 A AU2012229443 A AU 2012229443A AU 2012229443 B2 AU2012229443 B2 AU 2012229443B2
Authority
AU
Australia
Prior art keywords
hyperuricemia
gout
patient
diacerein
urate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012229443A
Other languages
English (en)
Other versions
AU2012229443A1 (en
Inventor
Chih-Kuang Chen
Mannching Sherry Ku
I-Yin Lin
Wei-Shu Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWi Biotechnology Inc
Original Assignee
TWi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWi Biotechnology Inc filed Critical TWi Biotechnology Inc
Publication of AU2012229443A1 publication Critical patent/AU2012229443A1/en
Application granted granted Critical
Publication of AU2012229443B2 publication Critical patent/AU2012229443B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012229443A 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia Ceased AU2012229443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (2)

Publication Number Publication Date
AU2012229443A1 AU2012229443A1 (en) 2013-09-12
AU2012229443B2 true AU2012229443B2 (en) 2017-03-02

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012229443A Ceased AU2012229443B2 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
US8865689B2 (en) 2011-03-11 2014-10-21 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
CA2983394A1 (en) * 2015-04-20 2016-10-27 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
AU2016287636B2 (en) * 2015-07-01 2021-09-16 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
JP6887987B2 (ja) * 2015-08-17 2021-06-16 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
KR101863604B1 (ko) 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
US20100104651A1 (en) * 2008-10-28 2010-04-29 Danchen Gao Pharmaceutical Compositions Containing Diacerein
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718469A2 (pt) * 2006-10-20 2014-01-21 Regeneron Pharma Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
EP2471515A3 (en) * 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US8865689B2 (en) 2011-03-11 2014-10-21 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US20100104651A1 (en) * 2008-10-28 2010-04-29 Danchen Gao Pharmaceutical Compositions Containing Diacerein

Also Published As

Publication number Publication date
RU2603050C2 (ru) 2016-11-20
JP6012639B2 (ja) 2016-10-25
BR112013022332A2 (pt) 2017-05-30
RU2013145498A (ru) 2015-04-20
MX2013010384A (es) 2013-10-07
IL228030A0 (en) 2013-09-30
KR101567885B1 (ko) 2015-11-10
AU2012229443A1 (en) 2013-09-12
WO2012125359A1 (en) 2012-09-20
TWI505827B (zh) 2015-11-01
EP2683372A1 (en) 2014-01-15
KR20140019795A (ko) 2014-02-17
CA2829101A1 (en) 2012-09-20
EP2683372A4 (en) 2014-08-06
MX350666B (es) 2017-09-12
ES2634562T3 (es) 2017-09-28
JP2014507476A (ja) 2014-03-27
NZ614486A (en) 2014-11-28
CN103429236B (zh) 2016-09-21
AR085662A1 (es) 2013-10-16
TW201249432A (en) 2012-12-16
PT2683372T (pt) 2017-10-25
EP2683372B1 (en) 2017-07-12
CN103429236A (zh) 2013-12-04
US8865689B2 (en) 2014-10-21
US20120232044A1 (en) 2012-09-13
IL228030B (en) 2018-01-31
CA2829101C (en) 2019-08-20

Similar Documents

Publication Publication Date Title
CA2829101C (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
RU2188013C2 (ru) Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
EP3038654B1 (en) New use
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
TW201414472A (zh) Ｓｇｌｔ２抑制藥與抗高血壓藥之組合
TW202143956A (zh) 用於糖尿病及其併發症治療的聯合用藥及其藥物組合物
CN101702884A (zh) 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
TW200409643A (en) Preventive agents for diabetes mellitus
CN104000814B (zh) 一种防治痛风性关节炎的药物组合物及其用途
KR20220168172A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물
US20100305074A1 (en) Niacin-based pharmaceutical compositions
AU782001B2 (en) Methods for treating cardiogenic shock using a nitric oxide synthase inhibitor
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2023526628A (ja) Ｅｒｃｐ後膵炎を予防するための組成物および方法
RU2008121841A (ru) Фармацевтическая комбинация таурина, тиоктовой кислоты и микронизированной флавоноидной фракции, фармацевтическая композиция, ее содержащая, и способ лечения
JP2010501604A (ja) グルコースレベルを低下させる方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired